Researchers present NorthPole – a brain-inspired chip architecture that blends computation with memory to process data efficiently at low-energy costs. Since its inception, computing has been ...
The AI boom shows no signs of slowing, but while training gets most of the headlines, it’s inferencing where the real business impact happens. Every time a chatbot answers, a fraud alert triggers or a ...
Inference Agents autonomously execute PhD-level analyses using Model Context Protocol (MCP) Platform now available to pharmaceutical research partners; powers collaborations totaling over $200 million ...
DGrid, a next-generation decentralized AI infrastructure, today announced its official launch in 2026, introducing a pioneering solution that combines decentralized architecture with advanced AI ...
SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Variant Bio, a genomics-driven AI drug discovery company, today announced the launch of Inference, the world's first agentic genomic drug discovery platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback